Kenneth Galbraith, Zymeworks CEO

Days af­ter flag­ging its $773M takeover bid, Zymeworks mi­nor­i­ty share­hold­er adds As­traZeneca on­col­o­gy vet to the crew

The in­vest­ment firm that launched an un­so­licit­ed takeover bid for Zymeworks has now brought in an As­traZeneca vet to help de­vise the fu­ture strat­e­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.